Troy Ignelzi Biography and Net Worth

Troy joins Rapport with nearly two decades of financial leadership experience in the biotech and pharmaceuticals sectors. Over the course of his career, Troy has raised an impressive $4 billion-plus in capital for life science companies. Most recently, he was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings. Prior to Karuna, Troy served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals. He has a long track record of experience in the sector, having started out at Eli Lilly and then moving on to roles of increasing responsibility at companies including Esperion Therapeutics and the former Insys Therapeutics. Previously, Troy served on the board of CinCor Pharma, Inc., where he advised on the company’s sale to AstraZeneca in early 2023. He currently serves on the boards of Vedanta Biosciences and Abivax. He is a graduate of Ferris State University, where he earned his B.S. in accounting.

What is Troy A. Ignelzi's net worth?: The estimated net worth of Troy A. Ignelzi is at least $284.13 thousand as of March 12th, 2025. Mr. Ignelzi owns 9,900 shares of Rapport Therapeutics stock worth more than $284,130 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Ignelzi may own. Learn More about Troy A. Ignelzi's net worth.
How do I contact Troy A. Ignelzi?: The corporate mailing address for Mr. Ignelzi and other Rapport Therapeutics executives is , , . Rapport Therapeutics can also be reached via phone at (857) 321-8020 and via email at [email protected]. Learn More on Troy A. Ignelzi's contact information.
Has Troy A. Ignelzi been buying or selling shares of Rapport Therapeutics?: Troy A. Ignelzi has not been actively trading shares of Rapport Therapeutics during the last quarter. Most recently, on Wednesday, March 12th, Troy A. Ignelzi bought 9,900 shares of Rapport Therapeutics stock. The stock was acquired at an average cost of $10.10 per share, with a total value of $99,990.00. Following the completion of the transaction, the chief financial officer now directly owns 9,900 shares of the company's stock, valued at $99,990. Learn More on Troy A. Ignelzi's trading history.
Who are Rapport Therapeutics' active insiders?: Rapport Therapeutics' insider roster includes James Healy (Director), Troy Ignelzi (CFO), and Wendy Young (Director). Learn More on Rapport Therapeutics' active insiders.
Are insiders buying or selling shares of Rapport Therapeutics?: During the last year, Rapport Therapeutics insiders bought shares 3 times. They purchased a total of 19,400 shares worth more than $240,350.00. During the last year, insiders at the sold shares 12 times. They sold a total of 145,752 shares worth more than $3,558,621.23. The most recent insider tranaction occured on November, 17th when CEO Abraham Ceesay sold 5,833 shares worth more than $146,933.27. Insiders at Rapport Therapeutics own 13.6% of the company. Learn More about insider trades at Rapport Therapeutics.
Information on this page was last updated on 11/17/2025.

Troy A. Ignelzi Insider Trading History at Rapport Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/12/2025	Buy	9,900	$10.10	$99,990.00	9,900

Troy A. Ignelzi Buying and Selling Activity at Rapport Therapeutics

Rapport Therapeutics Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Today's Range

Now: $28.70

$27.38

$29.32

50 Day Range

MA: $26.90

$24.37

$30.36

2 Week Range

Now: $28.70

$6.43

$42.27

Volume

474,346 shs

Average Volume

362,428 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63